The NAVIGATOR study, a large international placebo-controlled trial, did not demonstrate the validity of nateglinide (a short-acting insulin secretagogue) for reduction of the incidence of diabetes and cardiovascular events in the patients of impaired glucose tolerance [23]. Here, INS is linked to diabetes mellitus.